Comparison of Early and New Generation Drug ‐Eluting Stent Implantations for Ostial Right Coronary Artery Lesions
ConclusionsThe implantation of nDES for ostial RCA lesions significantly reduced the MACE rate compared with early generation DES, mainly driven by a reduction in the TLR rate. However, nDES implantations for ostial RCA lesions may still be challenging in patients with severe CKD.This article is protected by copyright. All rights reserved. (Source: Cardiovascular Therapeutics)
Source: Cardiovascular Therapeutics - December 30, 2016 Category: Cardiology Authors: Yusuke Watanabe, Kensuke Takagi, Toru Naganuma, Sunao Nakamura Tags: Original Research Article Source Type: research
HSP90 inhibition suppresses inflammatory response and reduces carotid atherosclerotic plaque formation in ApoE mice
ConclusionsThese findings suggested that HSP90 governs plaque development and vulnerability, as well as inflammation, at least in part via MMP‐8 and NF‐κB signaling pathways.This article is protected by copyright. All rights reserved. (Source: Cardiovascular Therapeutics)
Source: Cardiovascular Therapeutics - December 23, 2016 Category: Cardiology Authors: Hongmei Mu, Liyong Wang, Lei Zhao Tags: Original Research Article Source Type: research
The role of spironolactone on myocardial oxidative stress in rat model of streptozotocin ‐induced diabetes
ConclusionsThe increase in total nitrite/nitrotyrosine in DM promoted significant compensatory increases in antioxidant activities of SOD, catalase and glutathione peroxidase/reducatase probably to prevent cardiac oxidative damage. Use of spironolactone reduced nitrite generation and improved vitamin E levels independent of blood pressure.This article is protected by copyright. All rights reserved. (Source: Cardiovascular Therapeutics)
Source: Cardiovascular Therapeutics - December 19, 2016 Category: Cardiology Authors: Fadia Mayyas, Karem H. Alzoubi, Ruwidah Bonyan Tags: Original Research Article Source Type: research
Previous malignancy is an independent predictor of follow ‐up mortality after Percutaneous treatment of Mitral Valve regurgitation by means of MitraClip
ConclusionsPrevious neoplasm is a significant independent predictor of increased mortality after MVR with MitraClip. This association is even stronger than that of other cardiac and overall comorbidities and should be kept into consideration when referring patients for treatment.This article is protected by copyright. All rights reserved. (Source: Cardiovascular Therapeutics)
Source: Cardiovascular Therapeutics - December 18, 2016 Category: Cardiology Authors: Alper Öner, Hüseyin Ince, Liliya Paranskaya, Guido Schröder, Mohammad Sherif, Olga Thiele, Alla Neuhausen, Kische Stephan, Jasmin Ortak, Giuseppe D′Ancona Tags: Original Article Source Type: research
Platelet activating factor: A potential biomarker in acute coronary syndrome?
Summary
Platelet activating factor (PAF) is a potent pro‐inflammatory negotiator that shows distinct spectrum of biological and pharmacological effects. Importantly, it participates in a wide range of pathophysiological conditions. In cardiovascular system, PAF has been shown to have an important role in platelet and neutrophil aggregation, vascular permeability, microvascular leakage, thrombus formation, leukocyte adhesion to the endothelial cells, and initiation and progression of atherosclerosis. The purpose of this article was to review the PAF, a family of lipids that is associated with the pathology of coronary art...
Source: Cardiovascular Therapeutics - December 12, 2016 Category: Cardiology Authors: Anand Vijaya Kumar Palur Ramakrishnan, Treesa P. Varghese, Sreedevi Vanapalli, Narayanan K. Nair, Menge Denis Mingate Tags: Commissioned Article (Review) Source Type: research
Ezetimibe: Use, costs, and adverse events in Australia
ConclusionsEzetimibe use has increased rapidly in Australia since receiving public subsidy. Although the indications for subsidy are very restricted, there appears to have been widespread use, not explained by differential geographical IHD death rates. Latest guidelines still question the value of ezetimibe, so further discussion about whether the public spending on this medication for any potential improvement in population health outcomes is justified. (Source: Cardiovascular Therapeutics)
Source: Cardiovascular Therapeutics - December 12, 2016 Category: Cardiology Authors: Samantha A. Hollingworth, Remo Ostino, Michael C. David, Jennifer H. Martin, Susan E. Tett Tags: Original Research Article Source Type: research
Salidroside protects against homocysteine ‐induced injury in human umbilical vein endothelial cells via the regulation of endoplasmic reticulum stress
ConclusionsTaken together, these findings implicate that SAL could regulate ER stress pathway on the viability of endotheliocyte induced by Hcy in vitro. Our findings provide the first evidence that SAL plays an important role in endotheliocyte protection via suppressing ER stress pathway in HUVEC cells and that it may be a promising therapeutic target for atherosclerosis and cardiovascular disease. (Source: Cardiovascular Therapeutics)
Source: Cardiovascular Therapeutics - December 12, 2016 Category: Cardiology Authors: Lin Zhu, Fang Jia, Jiang Wei, Yang Yu, Tianhong Yu, Yanjun Wang, Jianhui Sun, Guanghua Luo Tags: Original Research Article Source Type: research
Rosuvastatin postconditioning protects isolated hearts against ischemia –reperfusion injury: The role of radical oxygen species, PI3K–Akt–GSK‐3β pathway, and mitochondrial permeability transition pore
ConclusionRosuvastatin prevents myocardial ischemia–reperfusion injury by inducing phosphorylation of PI3K–Akt and GSK‐3β, preventing oxidative stress and subsequent inhibition of mPTP opening. (Source: Cardiovascular Therapeutics)
Source: Cardiovascular Therapeutics - December 12, 2016 Category: Cardiology Authors: Chun ‐Wei Liu, Fan Yang, Shi‐Zhao Cheng, Yue Liu, Liang‐Hui Wan, Hong‐Liang Cong Tags: Original Research Article Source Type: research
Issue Information
(Source: Cardiovascular Therapeutics)
Source: Cardiovascular Therapeutics - December 12, 2016 Category: Cardiology Tags: Issue Information Source Type: research
Optimal pharmacological treatment and adherence to medication in secondary prevention of cardiovascular events in Spain. Results from the CAPS study
ConclusionsLow adherence to guideline‐oriented treatment as well as low adherence to medication was found by a self‐reported questionnaire. Enhancing adherence to guideline recommended therapy and reducing treatment complexity seem to be reasonable strategies to improve adherence to secondary prevention medications.This article is protected by copyright. All rights reserved. (Source: Cardiovascular Therapeutics)
Source: Cardiovascular Therapeutics - December 12, 2016 Category: Cardiology Authors: Alberto Cordero, Luis Rodriguez Padial, Alberto Batalla, Luis L ópez Barreiro, Francisco Torres Calvo, Jose M. Castellano, Emilio Ruiz, Vicente Bertomeu‐Martínez, Tags: Original Research Article Source Type: research
Protective Effects of Low Dose Rosuvastatin on Isoproterenol ‐induced Chronic Heart Failure in Rats by Regulation of DDAH‐ADMA‐NO Pathway
ConclusionsLow dose rosuvastatin exerted cardioprotective effects on isoproterenol‐induced heart failure in rats by modulating DDAH‐ADMA‐NO pathway, and it may present the new therapeutic value in ameliorating chronic heart failure.This article is protected by copyright. All rights reserved. (Source: Cardiovascular Therapeutics)
Source: Cardiovascular Therapeutics - November 30, 2016 Category: Cardiology Authors: Ru Zhou, Ping Ma, Aiqin Xiong, Yehua Xu, Yang Wang, Qingbin Xu Tags: Original Research Article Source Type: research
Photodynamic therapy for the treatment of atherosclerotic plaque: lost in translation?
This article is protected by copyright. All rights reserved. (Source: Cardiovascular Therapeutics)
Source: Cardiovascular Therapeutics - November 29, 2016 Category: Cardiology Authors: Manish Jain, Matthieu Zellweger, Georges Wagni ères, Hubert den Bergh, Stéphane Cook, Marie‐Noelle Giraud Tags: Unsolicited Review Source Type: research
Extended Dual Antiplatelet Therapy After Acute Coronary Syndrome in Spain: Results from the EPICOR Study
ConclusionsMore than half of patients in this unselected cohort study remained on DAPT at 2 years following discharge for ACS. Continuation with DAPT was greater among patients with additional cardiovascular risk factors, which suggests that treating physicians in Spain prioritize ischemic risk reduction over bleeding risk in ACS patients, according to patient risk profile.
Clinical Trial Registration—URLhttp://www.clinicaltrials.gov. Unique identifier: NCT01171404.This article is protected by copyright. All rights reserved. (Source: Cardiovascular Therapeutics)
Source: Cardiovascular Therapeutics - November 25, 2016 Category: Cardiology Authors: Alfredo Bardaj í, Manuel Leal, Vicente Arrarte, Xavier Garcia‐Moll, Leopoldo Pérez de Isla, Héctor Bueno Tags: Original Research Article Source Type: research
Ezetimibe: use, costs and adverse events in Australia
ConclusionsEzetimibe use has increased rapidly in Australia since receiving public subsidy. Although the indications for subsidy are very restricted there appears to have been widespread use, not explained by differential geographical IHD death rates. Latest guidelines still question the value of ezetimibe so further discussion about whether the public spending on this medication for any potential improvement in population health outcomes is justified.This article is protected by copyright. All rights reserved. (Source: Cardiovascular Therapeutics)
Source: Cardiovascular Therapeutics - November 18, 2016 Category: Cardiology Authors: Samantha A Hollingworth, Remo Ostino, Michael C David, Jennifer H Martin, Susan E Tett Tags: Original Research Article Source Type: research
Efficacy and Safety of Two Dosages of Canrenone as Add ‐On Therapy in Hypertensive Patients Taking Ace‐Inhibitors or Angiotensin II Receptor Blockers and Hydrochlorothiazide at Maximum Dosage in a Randomized Clinical Trial: The ESCAPE‐IT Trial
ConclusionBoth canrenone dosages gave a decrease of blood pressure, with a better effect with the higher dose, with only a slight increase of potassium and creatinine levels, which were not clinically relevant.This article is protected by copyright. All rights reserved. (Source: Cardiovascular Therapeutics)
Source: Cardiovascular Therapeutics - November 12, 2016 Category: Cardiology Authors: Giuseppe Derosa, Pamela Maffioli, Maria D'Avino, Carla Sala, Amedeo Mugellini, Vito Vulpis, Salvatore Felis, Luigina Guasti, Riccardo Sarzani, Alessandro Bestetti, Massimo Vanasia, Giovanni Gaudio, Tags: EXPEDITED ($1500) Source Type: research
